Chemours
$17.10
▲ +2.98%
+$0.50
NYSE · Basic Materials · Specialty Chemicals
· price updated 9h ago
CC · NYSE · Basic Materials · Specialty Chemicals · price updated 9h ago
$17.10
▲ +2.98% · +$0.50 today
AI research · $17.10
Operating record
Capital structure
Valuation
Forward P/E
Price against expected earnings
Favorable · 32% below Sector avg · favorable
10.20x
Price / sales
Value assigned to each sales dollar
Strong · Under 3x annual sales
0.43x
Price / FCF
Price against free cash generation
Strong · Under 20x free cash flow
16.22x
EV / EBITDA
Operating value including debt
Rich · Above 22x EBITDA
26.26x
Quality
ROIC
Return earned on invested capital
Weak · Below 8% return on capital
6.2%
ROE
Profit generated from shareholder equity
Needs attention · Among weakest in sector
-103.0%
Debt / equity
Balance-sheet leverage
Needs attention · Among weakest in sector
20.34x
Current ratio
Short-term assets against liabilities
Strong · Comfortable short-term liquidity
1.82x
Selected financial data sourced from StockAnalysis and refreshed weekly. Figures may be delayed and are for research context, not investment advice.
| company | mkt cap | P/E | rev growth | score |
|---|---|---|---|---|
| $2.50B | - | +0.6% | 52 | |
| $98.74B | 11.8 | +25.2% | 83 | |
| $9.47B | 20.3 | +66.3% | 81 | |
| $4.43B | 13.4 | +7.5% | 76 | |
| $90.03B | 30.8 | +0.2% | 70 |
US stock research
Chemours tracked in the US core universe. CC was +3.0% in the latest available session at $17.10. Its reported market value was $2.50B with a trailing P/E of 0.0. Latest reported revenue was $5.82B, changing +0.6% year over year, with $-411.00M in net income.
Market snapshot updated Aug 3, 2026, 7:59 PM UTC.